Business Wire

Democratising access to quantum computing: IQM Quantum Computers launches “IQM Spark” for universities and labs

30.8.2023 11:55:00 EEST | Business Wire | Press release

Share

IQM Quantum Computers (IQM), the European leader in building quantum computers, today launched “IQM Spark,” comprising a superconducting quantum computer and tailored learning experiences for universities and research labs worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830120669/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

IQM Spark quantum computer (Photo: Business Wire)

IQM Spark comes pre-installed with a 5-qubit quantum processing unit, with more options available allowing for a wide variety of research experiments.

To help universities kick-start their quantum program, in addition, universities will have free maintenance for one year, and IQM will also provide training for running the system and learning materials accessible through IQM Academy, a user-friendly online platform. With IQM Spark, students of all levels (bachelor, master, and PhD) will have the opportunity to learn hands-on about quantum computing.

Additionally, universities can also provide their students with the skillset needed for a quantum-enabled future by leveraging both hardware and software within the learning materials. With its technical track record and world-class expertise, IQM is also committed to collaborating with universities to drive advancements in quantum science.

Dr. Kuan Yen Tan, Chief Technology Officer and Co-founder of IQM Quantum Computers, said: “Since our inception, we’ve invested in and promoted quantum education and the advancement of research, and it’s apparent that universities around the globe need critical tools like IQM Spark to train the workforce needed for the next generation. Given the potential of quantum computing, the ecosystem will require a wide range of talent across electronics, chip fabrication, hardware design, and software engineering. We are confident that our system will facilitate the learning experience and engage students with the physical system.”

“We’ve designed this offering for universities and research labs to build up their quantum expertise and we believe that our system will not only perform fundamental quantum experiments and raise interest in Science, Technology, Engineering, and Mathematics (STEM) but we will also advance university science around quantum computing in general, while addressing the shortage of talent and providing value for the job market,” Dr. Björn Pötter, Head of Product at IQM Quantum Computers, points out.

IQM has already delivered 5-qubit quantum computers to some universities and research institutions, including the VTT Technical Research Centre of Finland and the Leibniz Supercomputing Centre in Germany. The quantum computer at VTT has been connected to LUMI, Europe’s most powerful supercomputer, hosted by the CSC - IT Center for Science.

“VTT and IQM successfully collaborated in delivering Finland’s first quantum computer in 2021. The 5-qubit quantum computer enables users to take the first steps in developing quantum algorithms and learn how to utilise the new technology in practice”, said Pekka Pursula, Research Manager in Quantum Technologies at VTT.

“On-premises quantum hardware is only available from a very limited number of vendors. This fact alone makes it hard for us to provide this leading-edge hardware to our scientists. Pricing and missing learning resources make it even harder to make this leading-edge technology available for educational purposes for our students,” said Prof. Dr. Dieter Kranzlmüller, Chairman of the Board of Directors of the Leibniz Supercomputing Centre, which caters to all universities of Bavaria in Germany.

“IQM Spark will address three major challenges: availability, learning resources, and affordability. In that way, universities can give practical experience to the next generation of quantum computing experts,” he added.

“Making on-premises quantum computer hardware available to our scientists and students as a low-barrier resource will give a boost to scientific progress and educate the next generation of quantum experts. This paves the way for students in Bavarian universities, such as Ludwig Maximilian University of Munich (LMU) and Technical University of Munich (TUM) students, to become entrepreneurs in the field of quantum technologies and live up to the excellence claim of the Munich universities,” he concluded.

About IQM Quantum Computers:

IQM is the European leader in building quantum computers. IQM provides on-premises quantum computers for supercomputing centres and research labs and offers full access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique application-specific, co-design approach. IQM’s commercial quantum computers include Finland’s first commercial 54-qubit quantum computer with VTT, IQM-led consortium’s (Q-Exa) HPC quantum accelerator in Germany, and IQM processors will also be used in the first quantum accelerator in Spain. IQM has over 280 employees with offices in Paris, Madrid, Munich, Singapore, and Espoo.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sylwia Barthel de Weydenthal, Head of Marketing and Communications
Email: press@meetiqm.com
Mobile: +358505966629
www.meetiqm.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye